Page 4 - தீமிஸ் உயிர் அறிவியல் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from தீமிஸ் உயிர் அறிவியல். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In தீமிஸ் உயிர் அறிவியல் Today - Breaking & Trending Today

Merck ends COVID-19 vaccine program, cites inferior immune responses

Drugmaker Merck & Co on Monday said it will end development of its two COVID-19 vaccines, and will focus pandemic research on treatments, with initial efficacy data on an experimental oral antiviral expected by the end of March.
Merck said in a statement it will record a pretax discontinuation charge in the fourth quarter for vaccine candidate V591, which it acquired with the purchase of Austrian vaccine maker Themis Bioscience, and V590, developed with nonprofit research organization IAVI.
In early trials, both vaccines generated immune responses that were inferior to those seen in people who had recovered from COVID-19 as well as those reported for other COVID-19 vaccines, the company said. ....

United States , Ridgeback Bio , Shri Navaratnam , Themis Bioscience , Pfizer Inc , Moderna Inc , Astrazeneca Plc , Drugmaker Merck Co On , Drugmaker Merck , Reporting By Deena Beasley Editing , ஒன்றுபட்டது மாநிலங்களில் , ரிட்ஜ்பேக் உயிர் , திரு நவரட்னம் , தீமிஸ் உயிர் அறிவியல் , ஃபைசர் இன்க் , மாடர்னா இன்க் , புகாரளித்தல் வழங்கியவர் தீனா பீஸ்லி திருத்துதல் ,

Merck ends COVID vaccine program, cites inferior immune responses

3 Min Read
Jan 25 (Reuters) - Drugmaker Merck & Co on Monday said it will end development of its two COVID-19 vaccines, and will focus pandemic research on treatments, with initial efficacy data on an experimental oral antiviral expected by the end of March.
Merck said in a statement it will record a pretax discontinuation charge in the fourth quarter for vaccine candidate V591, which it acquired with the purchase of Austrian vaccine maker Themis Bioscience, and V590, developed with nonprofit research organization IAVI.
In early trials, both vaccines generated immune responses that were inferior to those seen in people who had recovered from COVID-19 as well as those reported for other COVID-19 vaccines, the company said. ....

United States , Ridgeback Bio , Deena Beasley , Shri Navaratnam , Themis Bioscience , Thomson Reuters Trust Principles , Astrazeneca Plc , Drugmaker Merck Co On , Pfizer Inc , Moderna Inc , Reporting By Deena Beasley Editing , Thomson Reuters Trust , Coronavirus Merck , Corona Virus , Drug Amp Device Development , General News , General Health , Health Medicine , Healthcare Trbc Level 1 , Human Diseases Conditions , Infectious Diseases , North America , Pharmaceuticals Amp Medical Research Trbc Level 2 , Science Technology , ஒன்றுபட்டது மாநிலங்களில் , ரிட்ஜ்பேக் உயிர் ,

Merck exits COVID-19 vaccine development, cites disappointing data

Merck is shutting down the programs linked to its two COVID-19 vaccine candidates following early trial data indicating that they failed to generate immune responses comparable to a natural infection or existing vaccines.
One of its candidates against COVID-19 was called V590; it built on Merck’s Ebola inoculation platform, while the other one, V591, was based on a measles vaccine used in Europe.
Merck, known as MSD outside of the US and Canada, will record a pretax charge in Q4, 2021 as a result of halting the programs related to V591, which it acquired with the purchase of Austrian vaccine maker, Themis Bioscience, and V590, developed with nonprofit research organization, IAVI. ....

Kenneth Frazier , Ridgeback Biotherapeutics , Ridgeback Bio , Themis Bioscience , Coalition For Epidemic Preparedness Innovations , Epidemic Preparedness Innovations , Harvard Business School , கெநெத் ப்ராஜிேர் , ரிட்ஜ்பேக் உயிர் , தீமிஸ் உயிர் அறிவியல் , கூட்டணி க்கு பெருவாரியாக பரவும் தொற்று நோய் ப்ரிப்யாரெட்நெஸ் புதுமைகள் , பெருவாரியாக பரவும் தொற்று நோய் ப்ரிப்யாரெட்நெஸ் புதுமைகள் , ஹார்வர்ட் வணிக பள்ளி ,

Cancer Vaccines Global Market Report 2020-30: COVID-19 Growth and Change

Share:
New York, Dec. 10, 2020 (GLOBE NEWSWIRE) Reportlinker.com announces the release of the report Cancer Vaccines Global Market Report 2020-30: COVID-19 Growth and Change - https://www.reportlinker.com/p05995337/?utm source=GNW
21 billion in 2019 to $4.89 billion in 2020 at a compound annual growth rate (CAGR) of -6.16%. The decline is mainly due to the COVID-19 outbreak that has led to restrictive containment measures involving social distancing, remote working, and the closure of industries and other commercial activities resulting in operational challenges. The entire supply chain has been disrupted, impacting the market negatively. The market is then expected to recover and reach $7.61 billion in 2023 at a CAGR of 15.85%. ....

United States , New York , Khloris Biosciences , Themis Bioscience , World Health Organization , American Cancer Society , Vaccines Global Market Report , ஒன்றுபட்டது மாநிலங்களில் , புதியது யார்க் , தீமிஸ் உயிர் அறிவியல் , உலகம் ஆரோக்கியம் ஆர்கநைஸேஶந் , அமெரிக்கன் புற்றுநோய் சமூகம் , தடுப்பு மருந்துகள் உலகளாவிய சந்தை அறிக்கை ,